Skip to content
All Sections
Subscribe Now
60°F
Monday, July 1st 2024
Today's E-Edition
Home Page
Close Menu
Business
Technology
Commercial Real Estate
Housing
Marketplace
The Mercury News
SUBSCRIBE NOW
Close Menu
Morning Report in your inbox!
Sign Up
Subscribe
Account Settings
Contact Us
Log Out
Spoof a user
Morning Report in your inbox!
Sign Up
Subscribe
Search
Silicon Valley
60°F
Monday, July 1st 2024
Today's E-Edition
Business
Technology
Commercial Real Estate
Housing
Marketplace
The Mercury News
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Agenus Inc.
< Previous
1
2
Next >
Significant Tumor Reductions in Neoadjuvant MSS Colon Cancer Patients Treated with Botensilimab/Balstilimab Presented at ESMO GI Conference
June 28, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Cancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical Studies
June 27, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors
June 17, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus Announces Virtual Annual Shareholders Meeting
June 04, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 24, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting
May 23, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
May 23, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal Cancer
May 16, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus Reports First Quarter 2024 Results
May 07, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement
May 01, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting
April 24, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus to Provide First Quarter 2024 Financial Report and Corporate Update
April 23, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer
April 12, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus Announces Reverse Stock Split of Common Stock
April 05, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus Reports Fourth Quarter and Full Year 2023 Results
March 14, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024
March 06, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 05, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
February 29, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus to Participate in Leerink Partners Global Biopharma Conference
February 26, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
January 31, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Botensilimab/Balstilimab Breakthrough Data Presented at ASCO-GI Shows Unprecedented Tumor Shrinkage and Robust Biomarker Response in Prevalent Colorectal Cancer Population
January 22, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 05, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus to Participate in B. Riley Healthcare Conference
January 04, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Botensilimab/Balstilimab Data in Neoadjuvant Colorectal Cancer Selected for ASCO-GI 2024
December 20, 2023
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus to Receive $25 Million Milestone Payment from Bristol Myers Squibb for TIGIT-CD96 Bispecific Program
December 11, 2023
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus Reports Third Quarter 2023 Results
November 07, 2023
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus to Provide Third Quarter 2023 Financial Report and Corporate Update
October 26, 2023
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus Unveils New and Updated Botensilimab Data in Colorectal, Pancreatic, Lung, Melanoma, and Sarcoma
October 22, 2023
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
ESMO 2023: Agenus’ Botensilimab/Balstilimab Combination Delivers Durable Responses across Multiple Sarcoma Subtypes
October 21, 2023
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus Completes Enrollment in Randomized Phase 2 Clinical Trial of Botensilimab/Balstilimab in Advanced Colorectal Cancer
October 10, 2023
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close